Search

EHA-PTHiT Hematology Mini Tutorial

Dates: April 12-13, 2021
Location: VIRTUAL
Chairs: I Hus (Poland), T Robak (Poland) & G Gaidano (Italy)

As a prelude to the full Tutorial planned for later this year, EHA and the Polish Society of Hematology and Transfusion (PTHiT) present a virtual 'mini…

Read more

SWG Grant-funded projects, 2025

In November and December 2024, SWGs were invited to develop project ideas and apply for a 2025 SWG Grant. For the 2025 call, EHA offered five grants, each worth €30,000.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Great new opportunity for the YoungEHA community!

Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee

The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!

 

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia 

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…

Read more

Chairs and Members

Chair (2020–2025 term)Prof Raúl Córdoba (Spain)

Vice-chairProf Valentín Goede (Germany)

SWG Executive Board
Sonja Zweegman (The Netherlands)—interest in multiple myeloma
Tamas Fulop (Canada)—interest in geriatrics and immunology
Giuseppe Rossi (Italy)—interest in indolent lymphomas
Dominique Bron (Belgium)—interest in lymphoma, CLL, and cognitive impairment
Sergio Storti (Italy)—interest in aggressive…

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more